I think it is there job to answer question and it will resolve certain uncertainties that are arising around these trials that we as people of this world and future payers of this medicin are allowed to question. I think it is good to ask question. Maybe they will discover that a FAQ page would be a good idea on their website.Could I politely suggest that we try not to inundate the doctors at Autifony with emails? It's not going to bring the trials any closer, and the only outcomes I can see are a) they stop responding to emails or b) they take the time to respond, despite the delays it means in actually getting the trial up-and-running.
Just a thought, not trying to pressure anybody.
Maybe they will discover that a FAQ page would be a good idea on their website.
Im sure they have customer service that isnt effecting the production line right?I'd like to think most serious researchers would not spend much time, if any, answering random emails. Most receive dozens on various subjects each day. Personally I'd rather they spend more time in the lab. Service is a large time sink.
Im sure they have customer service that isnt effecting the production line right?
These are all small companies. By "these", I mean Auris Medical, Autifony, GenVec, etc.
Number Of Employees
1) Auris Medical = 8
2) Autifony = 9
3) GenVec = 11
It's unclear whether the above employees only include people officially working at headquarter entities (ie. there could be other background personnel). But generally, these are small companies - for sure they would not have a customer service unit. This can also be seen by their raised capital - which is quite modest given that they don't make a turnover (yet); admittedly, Auris Medical was listed as having M$ 3 in revenue sales, but I don't know where that would come from since they don't have a finished product yet and therefore nothing "to sell" (not sure the info is accurate; haven't had time to double check it).
Raised Capital
1) Auris Medical = M$ 65,4 (as per official company financial information, data release of AM101 Phase III is scheduled for completion by EOY 2015; I would assume this means that the finished product cannot be released to market before 2016 - at the earliest - but I could be wrong; phase II and III could be run separately).
2) Autifony = M$ 25,4 (officially Autifony has two products listed (both named AUT00063) - one for tinnitus and one for hearing loss, but I believe it is the same product listed twice over; startup for Phase IIa is officially scheduled for 2014 as per financial information).
3) GenVec = M$ 176,7 (this raised capital would probably also be used for other purposes than hearing loss R&D; GenVec has two products listed - both being preclinical; clinical trial for CGF166 hearing loss is scheduled for startup in 2014 as per financially listed information).
As I work in finance, I have often used financial information as a source of indirect company information. I don't normally track down information on medical companies, but the above information is at least "roughly accurate".
So I agree with some of the earlier posts; stop contacting them unless absolutely necessary - they don't have the manpower. Often it is the CEO him- or her-self responding to phone calls and e-mails. My advice.
These are all small companies. By "these", I mean Auris Medical, Autifony, GenVec, etc.
Number Of Employees
1) Auris Medical = 8
2) Autifony = 9
3) GenVec = 11
It's unclear whether the above employees only include people officially working at headquarter entities (ie. there could be other background personnel). But generally, these are small companies - for sure they would not have a customer service unit. This can also be seen by their raised capital - which is quite modest given that they don't make a turnover (yet); admittedly, Auris Medical was listed as having M$ 3 in revenue sales, but I don't know where that would come from since they don't have a finished product yet and therefore nothing "to sell" (not sure the info is accurate; haven't had time to double check it).
Raised Capital
1) Auris Medical = CHF 75M (as per official company financial information, data release of AM101 Phase III is scheduled for completion by EOY 2015; I would assume this means that the finished product cannot be released to market before 2016 - at the earliest - but I could be wrong; phase II and III could be run separately).
2) Autifony = $ 25,4M (officially Autifony has two products listed (both named AUT00063) - one for tinnitus and one for hearing loss, but I believe it is the same product listed twice over; startup for Phase IIa is officially scheduled for 2014 as per financial information).
3) GenVec = $ ?M (this raised capital would probably also be used for other purposes than hearing loss R&D; GenVec has two products listed - both being preclinical; clinical trial for CGF166 hearing loss is scheduled for startup in 2014 as per financially listed information).
As I work in finance, I have often used financial information as a source of indirect company information. I don't normally track down information on medical companies, but the above information is at least "roughly accurate".
So I agree with some of the earlier posts; stop contacting them unless absolutely necessary - they don't have the manpower. Often it is the CEO him- or her-self responding to phone calls and e-mails. My advice.
interesting power point presentation from them.......
http://www.anglonordicbiotech.com/img/File/Comp Pres 2014/Autifony-session 1.pdf
Autifony Priorities
Chronic, subjective tinnitus
Reduce the perception and annoyance of tinnitus
Reducing the perception and annoyance.. Meaning lowering the T volume making it less annoying?
Yep.Reducing the perception and annoyance.. Meaning lowering the T volume making it less annoying?
Yep.
Like they mention in the presentation, the only way to hear tinnitus is if your brain perceives it. For most people, even with damaged hair cells, the signal never reaches the brain, thus, they never perceive the sound. The drug targets the mechanism that isn't functioning up to snuff, and will lower the volume of the tinnitus perceived by regulating the Kv3 ion channels that "control the activity of key neural elements." Apparently, these guys are supposed to prevent you from hearing signals if you damage your hearing, but in some of us, they're not as strong. This drug is supposed to amp them up so they catch the signal and prevent it from getting to the brain. That would stop the tinnitus.
Know what i mean though? What do you think? You think its really like concrete stuck in our brain and no way to escape? Just sounds ridiculous.. Theres always a way to figure shit out and it seems like there thinkin this may break the "chronic" cycle rather then acute cause there soo "different" bs.Now you're catching on folks
Yeah.. But isnt it true that some have gotten the lidocaine shot and it did not suppress their T?by the way lidocaine is a Kv7 potassium channel modulator - do the math.
Know what i mean though? What do you think? You think its really like concrete stuck in our brain and no way to escape? Just sounds ridiculous.. Theres always a way to figure shit out and it seems like there thinkin this may break the "chronic" cycle rather then acute cause there soo "different" bs.
Yes its true, but again Kv7 channels aren't auditory as far as I know.Yeah.. But isnt it true that some have gotten the lidocaine shot and it did not suppress their T?
What do you mean? That we'll have to take the pill every 3 minutes? If so I want it in chewing gum form lolby the way lidocaine is a Kv7 potassium channel modulator - do the math.
by the way lidocaine is a Kv7 potassium channel modulator - do the math....
...Kv7 channels aren't auditory as far as I know.
Lidocaine may indirectly modulate kv3 channels (Autifony's target), hence working in some and not others
Now you're catching on folks ....